ES2193069T3 - Formulacion farmaceutica en aerosol. - Google Patents

Formulacion farmaceutica en aerosol.

Info

Publication number
ES2193069T3
ES2193069T3 ES00925450T ES00925450T ES2193069T3 ES 2193069 T3 ES2193069 T3 ES 2193069T3 ES 00925450 T ES00925450 T ES 00925450T ES 00925450 T ES00925450 T ES 00925450T ES 2193069 T3 ES2193069 T3 ES 2193069T3
Authority
ES
Spain
Prior art keywords
formulations
aerosol
pharmaceutical formulation
relates
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00925450T
Other languages
English (en)
Inventor
Cecile Isabelle Bonvoisin
Christophe Laroche
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9921289.6A external-priority patent/GB9921289D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2193069T3 publication Critical patent/ES2193069T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una formulación farmacéutica en aerosol que comprende: (A) xinafoato de salmeterol en forma de partículas revestidas mediante secado por pulverización con al menos un tensioactivo en ausencia de cualquier otro excipiente de revestimiento, en suspensión en (B) un gas licuado como propelente que es 1, 1, 1, 2, 3, 3, 3-heptafluoro-n-propano o 1, 1, 1, 2-tetrafluoroetano y mezclas de los mismos.
ES00925450T 1999-04-14 2000-04-13 Formulacion farmaceutica en aerosol. Expired - Lifetime ES2193069T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BH12699 1999-04-14
GBGB9921289.6A GB9921289D0 (en) 1999-09-10 1999-09-10 Pharmaceutical aerosol formulation

Publications (1)

Publication Number Publication Date
ES2193069T3 true ES2193069T3 (es) 2003-11-01

Family

ID=25663377

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00925450T Expired - Lifetime ES2193069T3 (es) 1999-04-14 2000-04-13 Formulacion farmaceutica en aerosol.

Country Status (10)

Country Link
US (1) US7090831B1 (es)
EP (1) EP1169019B1 (es)
JP (1) JP2002541183A (es)
AT (1) ATE233084T1 (es)
AU (1) AU4417500A (es)
DE (1) DE60001492T2 (es)
DK (1) DK1169019T3 (es)
ES (1) ES2193069T3 (es)
PT (1) PT1169019E (es)
WO (1) WO2000061108A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080064613A1 (en) * 2006-09-11 2008-03-13 M-I Llc Dispersant coated weighting agents
EP1337239B2 (en) 2000-11-30 2015-11-25 Vectura Limited Particles for use in a pharmaceutical composition
ES2587135T3 (es) 2000-11-30 2016-10-20 Vectura Limited Procedimiento de fabricación de partículas para su uso en una composición farmacéutica
KR100881258B1 (ko) * 2000-12-22 2009-02-05 글락소 그룹 리미티드 살메테롤 지나포에이트를 위한 정량식 흡입기
CA2459493C (en) * 2001-09-14 2011-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg New pharmaceutical compositions for inhalation
AU2003259910A1 (en) * 2002-08-14 2004-03-03 E.I. Du Pont De Nemours And Company Process for coating a pharmaceutical particle
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
EP1628641A2 (en) * 2003-05-19 2006-03-01 Baxter International Inc. Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers
GB0321607D0 (en) † 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
EP1688169A4 (en) * 2003-11-28 2008-10-01 Mitsubishi Chem Corp PROCESS FOR PRODUCING FINE PARTICLES OF AN ORGANIC COMPOUND
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
EP1833822A2 (en) 2004-08-16 2007-09-19 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
WO2009069619A1 (ja) * 2007-11-27 2009-06-04 Erc Technology Inc. オゾン化界面活性剤を含有する新規組成物
EP3620154A1 (en) 2009-02-06 2020-03-11 University Of Southern California Therapeutic compositions comprising monoterpenes
SI3106149T1 (sl) 2009-05-29 2020-07-31 Pearl Therapeutics, Inc. Sestavki za pljučno dostavo muskarinskih antagonistov z dolgotrajnim delovanjem in agonistov beta-2 adrenergičnega receptorja z dolgotrajnim delovanjem in povezani postopki in sistemi
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
HUE026414T2 (hu) 2009-07-15 2016-05-30 Theravance Biopharma R&D Ip Llc Bifenil-vegyület kristályos szabad-bázis formája
BR112012022209A2 (pt) 2010-03-03 2017-06-06 Neonc Tech Inc composições farmacêuticas compreendendo monoterpenos
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
CN105078973B (zh) 2010-08-27 2020-10-09 尼昂克技术公司 包含poh衍生物的药物组合物
CN105616391B (zh) 2010-12-17 2021-03-19 尼昂克技术公司 使用异紫苏醇的方法和装置
ES2704465T3 (es) 2011-10-11 2019-03-18 Chiesi Farm Spa Micropartículas cristalinas de un agonista de beta recubierto con un ácido graso
US9700558B2 (en) 2013-03-15 2017-07-11 Verona Pharma Plc Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonist
HK1219059A1 (zh) 2013-03-15 2017-03-24 珍珠治疗公司 用於微粒晶体材料的状态调节的方法和系统
DE102013021718B4 (de) * 2013-12-20 2017-03-02 Gerresheimer Regensburg Gmbh Kapsel zur Verwendung als Reservoir für eine pharmazeutische, vorzugsweise pulverförmige Zubereitung in einem Inhalator sowie Inhalator dafür
SI3142701T1 (en) 2014-05-12 2018-08-31 Verona Pharma Plc NEW TREATMENT
EP3872069A1 (en) 2015-02-12 2021-09-01 Neonc Technologies, Inc. Pharmaceutical compositions comprising perillyl alcohol derivatives
DK3547836T3 (da) 2016-11-30 2024-11-18 Univ Southern California Perillylalkohol-3 brompyruvat-konjugat og fremgangsmåder til behandling af cancer
CN119868317A (zh) 2018-02-08 2025-04-25 南加州大学 穿透血脑屏障的方法
WO2021216710A1 (en) 2020-04-24 2021-10-28 The Medical College Of Wisconsin, Inc. Use of salmeterol as an anti-coronaviral agent

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1535531A (en) * 1976-10-15 1978-12-13 Warmer & Co Ltd W Pharmaceutical compositions
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
WO1988001165A1 (en) 1986-08-11 1988-02-25 Innovata Biomed Limited Pharmaceutical formulations comprising microcapsules
GB8921222D0 (en) 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
AU7908791A (en) 1990-05-08 1991-11-27 Liposome Technology, Inc. Direct spray-dried drug/lipid powder composition
GB9024366D0 (en) 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
GB9024365D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
GB9026005D0 (en) 1990-11-29 1991-01-16 Glaxo Group Ltd Drug material suitable for micronisation
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
DE69227257T2 (de) 1991-12-12 1999-03-25 Glaxo Group Ltd Arzneimittel
ES2089357T3 (es) 1991-12-31 1996-10-01 Hoechst Ag Formulacion medicinal en forma de aerosol.
MX9304585A (es) 1992-07-31 1994-03-31 Glaxo Group Ltd Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
EP0655237A1 (de) * 1993-11-27 1995-05-31 Hoechst Aktiengesellschaft Medizinische Aerosolformulierung
GB9419536D0 (en) * 1994-09-28 1994-11-16 Glaxo Inc Medicaments
JPH08151322A (ja) * 1994-09-30 1996-06-11 Takeda Chem Ind Ltd 経口徐放剤
GB9425160D0 (en) * 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
GB9606188D0 (en) 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
JP2001507701A (ja) 1996-12-31 2001-06-12 インヘイル・セラピューティック・システムズ・インコーポレーテッド 親水性賦形剤を有する疎水性薬剤の溶液を噴霧乾燥するための方法及びその方法によって作製された組成物
JP2002512183A (ja) * 1998-04-18 2002-04-23 グラクソ グループ リミテッド 医薬用エアゾール製剤
GB9828721D0 (en) 1998-12-24 1999-02-17 Glaxo Group Ltd Novel apparatus and process

Also Published As

Publication number Publication date
PT1169019E (pt) 2003-07-31
DE60001492D1 (de) 2003-04-03
DE60001492T2 (de) 2003-12-18
AU4417500A (en) 2000-11-14
US7090831B1 (en) 2006-08-15
WO2000061108A1 (en) 2000-10-19
EP1169019A1 (en) 2002-01-09
DK1169019T3 (da) 2003-06-02
JP2002541183A (ja) 2002-12-03
ATE233084T1 (de) 2003-03-15
EP1169019B1 (en) 2003-02-26

Similar Documents

Publication Publication Date Title
DK1169019T3 (da) Farmaceutisk aerosolformulering
AP2000001961A0 (en) Pharmaceutical aerosol formulation.
DE60123793D1 (de) Neue aerosolformulierungen ein polares fluoriniertes molekül enthaltend
ES2178817T3 (es) Formulaciones medicinales de aerosol.
IT1255040B (it) Forma di ciclosporina adatta alla somministrazione per via polmonare eprocedimento di preparazione.
NZ240237A (en) An aerosol formulation (free of surfactant) for treatment of asthma comprising: a hydrofluorocarbon propellant, ethanol, and beclomethasone 17,21 dipropionate; preparation thereof
CA2338753A1 (en) Medicinal aerosol formulations
NO20025593D0 (no) Aerosolbeholder for formuleringer av salmeterol-xinafoat
ATE366568T1 (de) Aerosolformulierungen von salmeterol xinafoate
ATE398999T1 (de) Aerosol-formulierungen von formoterol und mometason
AU2206801A (en) Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
HUP0002691A2 (hu) Ciklezonid tartalmú gyógyászati aeroszol termékek
CA2441549A1 (en) Ipratropium formulation for pulmonary inhalation
DE69102161D1 (de) Gemische von Dimethyläther und 1,1,1,2-Tetrafluoräthan und deren Verwendungen.
WO2002076176A3 (en) Mixtures containing 1,1,1,3,3-pentafluoropropane and 1,1,1,3,3-pentafluorobutane
WO1999024016A8 (en) Emulsions for aerosolization and drug delivery
AU1534501A (en) Pharmaceutical formulations of salmeterol
ECSP972240A (es) Formulaciones en aerosol de furoato de mometasona sin clorofluorocarburos